AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

01 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

15 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

08 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021

20 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million

18 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy

16 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine

14 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder

23 Aug 2021 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

09 Aug 2021 07:05:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2021 Financial Results on August 9, 2021

15 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia

15 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

10 May 2021 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health Month

07 May 2021 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report First Quarter 2021 Financial Results on May 10, 2021

27 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder

26 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

01 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Upcoming Investor Conferences

19 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

16 Feb 2021 07:00:02 By Nasdaq GlobeNewswire